Healthcare Global Enterprises Li (NSE: HCG, BSE: 539787) is a Bengaluru, Karnataka-based company in the Hospitals and Healthcare Centers industry. With a market capitalisation of ₹8,444 Cr, it ranks #648 by market cap among the 6,197 Indian listed companies on FinBizNet, and #15 of 46 in Hospitals and Healthcare Centers. At ₹569.05 (as of 16 Nov 2026), the share price is 26.6% below its 52-week high of ₹775.00 and 10.9% above its 52-week low of ₹513.30. The share price is down 24.6% over one year and down 20.6% over three months.
| Current Price | ₹569.05 |
|---|---|
| Market Cap | ₹8,444 Cr |
| NSE Symbol | HCG |
| BSE Code | 539787 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Facilities > Hospitals and Healthcare Centers |
| P/E Ratio | 595.5 |
| Return on Equity | 1.90% |
| Return on Assets | 3.81% |
| 52-Week Range | ₹513.30 – ₹775.00 |
| 1-Year Price Change | -24.6% |
| 3-Month Price Change | -20.6% |
| Beta (1Y) | 0.31 |
| Headquarters | Bengaluru, Karnataka |
| Website | www.hcgoncology.com |
| Revenue | ₹732 Cr |
|---|---|
| Net Profit | ₹9 Cr |
| Net Margin | 1.3% |
| EPS (Basic) | ₹0.32 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Healthcare Global Enterprises Li reported revenue of ₹732 Cr in Q2 FY27, up 13.1% from ₹647 Cr in Q2 FY26 and up 5.3% from ₹695 Cr in Q1 FY27. It posted a net profit of ₹9 Cr for the quarter, against a net profit of ₹21 Cr in Q2 FY26 (down 55.2%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹585 Cr (Q4 FY25) to ₹732 Cr (Q2 FY27). The company reported a net loss in 1 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹732 Cr | ₹9 Cr | 1.3% |
| Q1 FY27 | ₹695 Cr | ₹16 Cr | 2.4% |
| Q4 FY26 | ₹652 Cr | ₹4 Cr | 0.6% |
| Q3 FY26 | ₹633 Cr | −₹8 Cr | −1.2% |
| Q2 FY26 | ₹647 Cr | ₹21 Cr | 3.2% |
| Q1 FY26 | ₹613 Cr | ₹6 Cr | 1.0% |
| Q4 FY25 | ₹585 Cr | ₹7 Cr | 1.2% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 64.21% of Healthcare Global Enterprises Li's shares as of Sept 2026, against 63.78% in Sept 2025 (+0.43 percentage points). Delivery averaged 58.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services comprising patient care, psychological support, nutrition and dietetics, multidisciplinary rehabilitation, and genetic counselling. It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology,
1. Setting up and Managing Hospitals and Medical Diagnostic Services-This segment owns and operates cancer centers, diagnostic centers, fertility clinics, clinical reference laboratories, and multi-specialty hospitals.
1. Setting up and Managing Hospitals and Medical Diagnostic Services-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | ₹1,23,712 Cr | 63 | 21.50% | ₹7,615 Cr | +11.6% |
| Max Healthcare Institute Ltd | ₹91,978 Cr | 63.9 | 14.33% | ₹2,569 Cr | -16.6% |
| Manipal Health Enterprises Ltd | ₹89,110 Cr | 88.4 | — | ₹3,399 Cr | — |
| Aster Dm Healthcare Limited (Asterdm) | ₹63,041 Cr | 97.6 | 10.07% | ₹2,829 Cr | +4.3% |
| Fortis Healthcare Ltd. | ₹58,283 Cr | 55.1 | 11.01% | ₹2,735 Cr | -25.1% |
| Global Health Ltd (Medanta) | ₹38,422 Cr | 69.7 | 15.03% | ₹1,469 Cr | +16.2% |
| Narayana Hrudayalaya Limited | ₹37,907 Cr | 46.2 | 19.85% | ₹2,844 Cr | +2.8% |
| Krishna Institute Of Medical Science (KIMS) | ₹29,056 Cr | 120.6 | 9.72% | ₹1,344 Cr | +0.2% |
| Healthcare Global Enterprises Li | ₹8,444 Cr | 595.5 | 1.90% | ₹732 Cr | -24.6% |
Listed by market capitalisation. Ratios are shown for context only.
Healthcare Global Enterprises Li is trading at ₹569.05, with a market capitalisation of ₹8,444 Cr.
Healthcare Global Enterprises Li operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Facilities > Hospitals and Healthcare Centers).
Healthcare Global Enterprises Li has a P/E of 595.5 and a return on equity of 1.90%.
Healthcare Global Enterprises Li is listed on the NSE under the symbol HCG and on the BSE under the scrip code 539787.
Healthcare Global Enterprises Li's share price is down 24.6% over one year and down 20.6% over three months. Its 52-week range is ₹513.30 to ₹775.00.
In Q2 FY27, Healthcare Global Enterprises Li reported revenue of ₹732 Cr and net profit of ₹9 Cr, with basic EPS of ₹0.32 (consolidated, parsed from the company's exchange filing).
Healthcare Global Enterprises Li reported revenue of ₹732 Cr in Q2 FY27, up 13.1% from ₹647 Cr in Q2 FY26 and up 5.3% from ₹695 Cr in Q1 FY27.
Promoters held 64.21% of Healthcare Global Enterprises Li's shares as of Sept 2026, against 63.78% in Sept 2025 (+0.43 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.